Tags : Merck & Co’s

Merck & Co’s Dificid (fidaxomicin) Receives FDA’s Approval to Treat

Tuba Khan January 27, 2020

Shots: The US FDA has approved NDA for Dificid oral suspension and sNDA for Dificid tablets for the treatment of Clostridioides difficile-associated diarrhea (CDAD) in patients aged ≥6mos. The approval […]readmore

Tags : Merck & Co’s

Merck & Co’s Dificid (fidaxomicin) Receives FDA’s Approval to Treat

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Merck & Co’s

Merck & Co’s Dificid (fidaxomicin) Receives FDA’s Approval to Treat

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company